Immunohistochemical expression of PTEN in normal, hyperplastic and malignant endometrium and its correlation with hormone receptors, bcl-2, bax, and apoptotic index

Pathology Research and Practice

Volumn 203, Issue 3, 2007, Pages 153-162

  Kapucuoglu, Nilgun ^a   Aktepe, Fatma ^a   Kaya, Hakan ^a   Bircan, Sema ^a   Karahan, Nermin ^a   Çiriş, Metin ^a  

^a SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Apoptosis; Endometrial carcinoma; Estrogen receptor; Progesterone receptor; PTEN

Indexed keywords

EOSIN; ESTROGEN RECEPTOR; HEMATOXYLIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PROTEIN BAX; PROTEIN BCL 2;

ADULT; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER INVASION; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PHENOTYPE; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

EID: 33847320123     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2007.01.003     Document Type: Article

References (58)

1. An H.-J., Cho Y.-H., Shim J.Y., and Kim J.-Y. Alteration of PTEN expression in endometrial cancer is associated with down-regulation of cyclin-dependent kinase inhibitor, p27. Histopathology 41 (2002) 437-445
2. Bergeron C., Ferenczy A., Toft D.O., and Syhamala G. Immunocytochemical study of progesterone receptors in hyperplastic and neoplastic endometrial tissues. Cancer Res 48 (1998) 6132-6136
3. Bergeron C., Nogales F.F., Masseroli M., Abeler V., Duvillard P., Muller-Holzner E., Pickartz H., and Wells M. A multicentric European study testing the reproducibility of the WHO classification of endometrial hyperplasia with a proposal of a simplified working classification for biopsy and curettage specimens. Am J Surg Pathol 23 (1999) 1102-1108
4. Bozdoǧan O., Atasoy P., Erekul S., Bozdoǧan N., and Bayram M. Apoptosis-related proteins and steroid hormone receptors in normal, hyperplastic, and neoplastic endometrium. Int J Gynecol Pathol 21 (2002) 375-382
5. Bose S., Crane A., Hibshoosh H., Mansukhani M., Sandweis L., and Parsons R. Reduced expression of PTEN correlates with breast cancer progression. Hum Pathol 33 (2002) 405-409
6. Bussaglia E., Del Rio E., Matias-Guiu X., and Prat J. PTEN mutations in endometrial carcinomas: a molecular and clinicopathologic analysis of 38 cases. Hum Pathol 31 (2000) 312-317
7. Carr N.J. M30 expression demonstrates apoptotic cells, correlates with in situ end-labeling, and is associated with Ki-67 expression in large intestinal neoplasms. Arch Pathol Lab Med 124 (2000) 1768-1772
8. Creasman W.T. Gynecol Oncol 35 (1989) 125-127
9. Davies M.A., Koul D., Dhesi H., Berman R., McDonnell T.J., McConkey D., Yung W.K.A., and Steck P.A. Regulation of Akt/PKB activity, cellular growth and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res 59 (1999) 2551-2556
10. Di Cristofano A., and Pandolfi P.P. The multiple roles of PTEN in tumor suppression. Cell 100 (2000) 387-390
11. Fan X., Munoz J., Sanko S.G., and Castresana J.S. PTEN, DMBT1, and p16 alterations in diffusely infiltrating astrocytomas. Int J Oncol 21 (2002) 667-674
12. Hockenbery D.M. The bcl-2 oncogene and apoptosis. Semin Immunol 4 (1992) 413-420
13. Ioffe O.B., Papadimitriou J.C., and Drachenberg C.B. Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic, and malignant endometrium. Hum Pathol 29 (1998) 1150-1159
14. Kanamori Y., Kigawa J., Itamochi H., Shimada M., Takahashi M., Kamazawa S., Sato S., Akeshima R., and Terakawa N. Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. Clin Cancer Res 7 (2001) 892-895
15. Kimura F., Watanabe J., Hata H., Fujisawa T., Kamata Y., Nishimura Y., Jobo T., and Kuramoto H. PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus. J Cancer Res Clin Oncol 130 (2004) 161-168
16. Kokawa K., Shikone T., Otani T., Nishiyama R., Ishii Y., Yagi S., and Yamoto M. Apoptosis and the expression of bax and bcl-2 in hyperplasia and adenocarcinoma of the uterine endometrium. Hum Rep 16 (2001) 2211-2218
17. Konopka B., Paszko Z., Janiec-Jankowska A., and Goluda M. Assessment of the quality and frequency of mutations occurrence in PTEN gene in endometrial carcinomas and hyperplasias. Cancer Lett 178 (2002) 43-51
18. Koornstra J.J., Rijcken F.E.M., de Jong S., Hollema H., de Varies E.G.E., and Kleibeuker J.H. Assessment of apoptosis by M30 immunoreactivity and the correlation with morphologic criteria in normal colorectal mucosa, adenomas and carcinomas. Histopathology 44 (2004) 9-17
19. Koul A., Willien R., Bendahl P.-O., Nilbert M., and Borg A. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis. Cancer 94 (2002) 2369-2379
20. Kounelis S., Kapranos N., Kouri E., Coppola D., Papadaki H., and Jones M.W. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Mod Pathol 13 (2000) 379-388
21. Latta E., and Chapman W.B. PTEN mutations and evolving concepts in endometrial neoplasia. Cur Op Obstet Gynecol 14 (2002) 59-65
22. Lax S.F. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 444 (2004) 213-223
23. Lu Q.-L., Abel P., Foster C.S., and Lalani A.-N. Bcl-2: role in epithelial differentiation and oncogenesis. Hum Pathol 27 (1996) 102-110
24. Marone M., Ferrandina G., Macchia G., Mozzetti S., de Pasqua A., Benedetti-Panici P., and Mancuso S. Bcl-2 bax, bcl-XL and bcl-XS expression in neoplastic and normal endometrium. Oncology 58 (2000) 161-168
25. Mora L.B., Diaz J.I., Cantor A.B., and Nicosia S.V. Differential diagnosis of endometrial hyperplasia and carcinoma by computerized image cytometry of cell proliferation, apoptosis and bcl-2 expression. Ann Clin Lab Sci 29 (1999) 308-315
26. Morsi H.M., Leers M.P.G., Jager W., Bröjklund V., Radespiel-Tröger M., Kabarity H.E., Nap M., and Lang N. The patterns of expression of an apoptosis-related CK18 neoepitope, the bcl-2 proto-oncogene, and Ki67 proliferation marker in normal, hyperplastic and malignant endometrium. Int J Gynecol Pathol 19 (2000) 118-126
27. Matias-Guiu X., Catasus L., Bussaglia E., Lagarda H., Garcia A., Pons C., Munoz J., and Prat J. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 32 (2001) 569-577
28. Matsushima-Nishiu M., Unoki M., Ono K., Tsunoda T., Minaguchi T., Kuramoto H., Nishida M., Satoh T., Tanaka T., and Nakamura Y. Growth and gene expression profile analyses of endometrial cancer cells expressing exogenous PTEN. Cancer Res 61 (2001) 3741-3749
29. Mutter G.L., Lin M.-C., Fitzgerald J.T., Kum J.B., Baak J.P.A., Lees J.A., Weng L.-P., and Eng C. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 92 (2000) 924-931
30. Mutter G.L., Lin M.-C., Fitzgerald J.T., Kum J.B., and Eng C. Changes in endometrial PTEN expression throughout the human menstrual cycle. J Clin Endocrinol Metab 85 (2000) 2334-2338
31. Mutter G.L., Ince T.A., Baak J.P.A., Kust G.A., Zhou X.-P., and Eng C. Molecular identification of latent precancers in histologically normal endometrium. Cancer Res 61 (2001) 4311-4314
32. Mylonas I., Jeschke U., Shabani N., Khun C., Kriegel S., Kupka M.S., and Friese K. Normal and malignant human endometrium express immunohistochemically estrogen receptor alpha (ER-α), estrogen receptor beta (ER-β) and progesterone receptor (PR). Anticancer Res 25 (2005) 1679-1686
33. Oltvai Z.N., Milliman C.L., and Korsmeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death. Cell 74 (1993) 609-619
34. Orbo A., Nilsen M.N., Arnes M.S., Pettersen I., and Larsen K. Loss of expression of MLH1, MSH2, MSH6, and PTEN related to endometrial cancer in 68 patients with endometrial hyperplasia. Int J Gynecol Pathol 22 (2003) 141-148
35. Orejuela F.J., Ramondetta L.M., Smith J., Brown J., Lemos L.B., Li Y., and Hollier L.M. Estrogen and progesterone receptors and cyclooxygenase-2 expression in endometrial cancer, hyperplasia, and normal endometrium. Gynecol Oncol 97 (2005) 483-488
36. Peiro G., Diebold J., Baretton G.B., Kimmig R., and Löhrs U. Cellular apoptosis susceptibility gene expression in endometrial carcinoma: correlation with bcl-2, bax, and caspase-3 expression and outcome. Int J Gynecol Pathol 20 (2001) 359-367
37. Peiro G., Lohse P., Mayr D., and Diebold J. Insulin-like growth factor-I receptor and PTEN protein expression in endometrial carcinoma. Correlation with bax and bcl-2 expression, microsatellite instability status, and outcome. Am J Clin Pathol 120 (2003) 78-85
38. Podsypanina K., Ellenson L.H., Nemes A., Gu J., Tamura M., Yamada K.M., Cordon-Cardo C., Catoretti G., Fisher P.E., and Parsons R. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 96 (1999) 1563-1568
39. Risberg B., Karlsson K., Abeler V., Lagrelius A., Davidson B., and Karlsson M.G. Dissociated expression of bcl-2 and Ki-67 in endometrial lesions: diagnostic and histogenetic implications. Int J Gynecol Pathol 21 (2002) 155-160
40. Risinger J.I., Hayes K., Maxwell G.L., Carney M.E., Dodge R.K., Barrett J.C., and Berhuck A. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res 4 (1998) 3005-3010
41. Ronnett B.M., and Kurman R.J. Precursor lesions of endometrial carcinoma. In: Kurman R.J. (Ed). Blaustein's pathology of the female genital tract. 5th ed (2002), Springer, New York 467-470
42. Saegusa M., Kamata Y., Isono M., and Okayasu I. Bcl-2 expression is correlated with a low apoptotic index and associated with progesterone receptor immunoreactivity in endometrial carcinomas. J Pathol 180 (1996) 275-282
43. Sakuragi N., Salah-eldin A., Watari H., Itoh T., Inoue S., Moriuchi T., and Fujimoto S. Bax, bcl-2, and p53 expression in endometrial cancer. Gynecol Oncol 86 (2002) 288-296
44. Salvesen H.B., Stefansson I., Kalvenes M.B., Das S., and Aksien L.A. Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma. Cancer 94 (2002) 2185-2191
45. Silverberg S.G., Kurman R.J., Nogales F., Mutter G.L., Kubik-Huch R.A., and Tavassoli F.A. Epithelial tumours and related lesions. In: Tavassoli F.A., and Devilee P. (Eds). World Health Organization Classification of Tumors. Pathology and genetics of tumours of the breast and female genital organs, (2003), IARC Press, Lyon 221-232
46. Sivridis E., Giatromanolaki A., Koukourakis M., and Anastasiadis P. Endometrial carcinoma: association of steroid hormone receptor expression with low angiogenesis and bcl-2 expression. Virchows Arch 438 (2001) 470-477
47. Taskin M., Lallas T.A., Barber H.R.K., and Shevchuk M.M. Bcl-2 and p53 in endometrial adenocarcinoma. Mod Pathol 10 (1997) 728-734
48. Tao X.-J., Tilly K.I., Maravei D.V., Shifren J.L., Krajewski S., Reed J.C., Tilly J.L., and Isaacson K.B. Differential expression of members of the bcl-2 gene family in proliferative and secretory human endometrium: glandular epithelial cell apoptosis is associated with increased expression of bax. J Clin Endocrinol Metab 82 (1997) 3738-3746
49. Terakawa N., Kanamori Y., and Yoshida S. Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. End Rel Cancer 10 (2003) 203-208
50. Vaskivuo T.E., Stenback F., and Tapanainen J.S. Apoptosis and apoptosis-related factors bcl-2, bax, tumor necrosis factor-α, and NF-κB in human endometrial hyperplasia and carcinoma. Cancer 95 (2002) 1463-1471
51. Visakorpi T. The molecular genetics of prostate cancer. Urology 62 (2003) 3-10
52. Watanabe H., Kanzaki H., Narukawa S., Inoue T., Katsuragawa H., Kaneko Y., and Mori T. Bcl-2 and fas expression in eutopic and ectopic endometrium during menstrual cycle in relation to endometrial cell apoptosis. Am J Obstet Gynecol 176 (1997) 360-368
53. Yamauchi N., Sakamoto A., Uozaki H., Iihara K., and Machinami R. Immunohistochemical analysis of endometrial adenocarcinoma for bcl-2 and p53 in relation to expression of sex steroid receptor and proliferative activity. Int J Gynecol Pathol 15 (1996) 202-208
54. Yoshinaga K., Sasano H., Furukawa T., Yamakawa H., Yuki M., Sato S., Yajima A., and Horii A. The PTEN, BAX and IGFIIR genes are mutated in endometrial atypical hyperplasia. Jpn J Cancer Res 89 (1998) 935-940
55. Zaino R.J., Kurman R.J., Diana K.L., and Morrow C.P. The utility of the revised International Federation of Gynecology and Obstetrics histologic grading of endometrial adenocarcinoma using a defined nuclear grading system. Cancer 75 (1995) 81-86
56. Zaino R.J. The logical patterns of the normal menstrual cycle: form follows function. In: Zaino R.J. (Ed). Interpretation of Endometrial Biopsies and Curettings (1996), Lippincott-Raven Publishers, Philadelphia 53-99
57. Zaino R.J., Kauderer J., Trimble C.L., Silverberg S.G., Curtin J.P., Lim P.C., and Gallup D.G. Reproducibility of the diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 106 (2006) 804-811
58. Zhu X., Kwon C.-H., Schlosshauer P.W., Ellenson L.H., and Baker S.J. PTEN induces G1 cell cycle arrest and decreases cyclin D3 levels in endometrial carcinoma cells. Cancer Res 61 (2001) 4569-4575